Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Alkylation of DNA interfering with replication and transcription" is not a specific molecular target but rather describes a **mechanism** by which certain drugs—primarily anticancer agents—exert their effects. Alkylating agents covalently attach alkyl groups to various sites on the DNA molecule. This chemical modification can cause significant structural changes that block essential cellular processes such as **DNA replication** and **transcription**, ultimately triggering cell death through apoptosis. The precise biological outcome depends on the site(s) modified within the nucleobases; for example, bulky adducts often cause severe stalling for RNA polymerase II during transcription elongation while smaller modifications may have subtler effects on fidelity or bypass efficiency[1][2][3]. Many classic chemotherapeutic drugs act through this general mechanism. However, "alkylation of DNA interfering with replication and transcription" does not refer to a single protein or receptor but rather an effect produced by multiple possible lesions at different sites within the genome. Because this entry refers broadly to a process/mechanism—not an individual gene product/protein/receptor—it is not considered a canonical therapeutic target per se. It should be replaced by more specific entries referring either to particular enzymes involved in repair pathways (e.g., O^6-methylguanine-DNA methyltransferase), drug classes (e.g., nitrogen mustards), or well-defined molecular targets if available. In summary: > "Alkylation of DNA interfering with replication and transcription" describes how certain chemicals modify nucleic acids at diverse positions causing blockage/stalling/mutagenesis during both genetic information copying (replication) and expression (transcription). This is exploited therapeutically in cancer treatment but is not itself a discrete molecular entity suitable for structured database targeting.[1][2][3][5]
Formation of covalent adducts between alkyl groups and DNA bases at various positions (*N*3 and *N*7 of adenine; *O*6 and *N*7 of guanine; *N*3, *O*2, and *N*4 of cytosine; *N*3, *O*2, and *O*4 of thymine)[1][3]; Blockage or stalling of RNA polymerase II during transcription elongation due to structural distortion or direct interference by the adduct[1][2][3]; Inhibition/blockage of DNA replication machinery leading to cell cycle arrest or apoptosis[5]
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alkylation of DNA interfering with replication and transcription.